IN THE SPOTLIGHT

FDA Approval of Sevabertinib Expands Treatment Options for HER2-Mutated NSCLC

FDA Approval of Sevabertinib Expands Treatment Options for HER2-Mutated NSCLC

Dr Le on the Clinical Significance of the FDA Approval of Sevabertinib for Locally Advanced/Metastatic HER2+ NSCLC

Dr Le on the Clinical Significance of the FDA Approval of Sevabertinib for Locally Advanced/Metastatic HER2+ NSCLC

Dr Le on the Mechanism of Action of Sevabertinib in HER2-Mutated NSCLC

Dr Le on the Mechanism of Action of Sevabertinib in HER2-Mutated NSCLC

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy

Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC)

Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC)